Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gemcitabine for relapsed or resistant lymphoma.

D G Savage1, S A Rule, M Tighe

  • 1Hematology/Oncology Division, Columbia University, New York, New York 10032, USA. savage@cuccfa.ccc.columbia.edu

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|July 25, 2000
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Measurement of ratios of νμ charged-current cross sections on C, Fe, and Pb to CH at neutrino energies 2-20 GeV.

Physical review letters·2014
Same author

[Brain abscess. Evaluation of prognostic factors: does the use of antibiotic prescribing protocols improve outcome?].

Anales de medicina interna (Madrid, Spain : 1984)·2009
Same author

Acute ischaemic cerebrovascular attack secondary to infusional 5-fluoruracil and cisplatin in a patient with advanced gastric cancer.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2009
Same author

Training in flexible intensive insulin therapy improves quality of life, decreases the risk of hypoglycaemia and ameliorates poor metabolic control in patients with type 1 diabetes.

Diabetes research and clinical practice·2009
Same author

Factors affecting survival and tumor recurrence in patients transplanted for hepatocellular carcinoma and coexistent hepatitis C virus.

Transplantation proceedings·2008

Gemcitabine shows promise for treating advanced lymphoma patients who have not responded to other therapies. This chemotherapy agent demonstrated acceptable safety and notable efficacy in heavily pre-treated individuals.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Gemcitabine's efficacy in hematological malignancies is not well-established.
  • Limited data exists on gemcitabine for relapsed or resistant lymphoma.

Purpose of the Study:

  • To assess the efficacy and safety of gemcitabine in patients with relapsed or resistant lymphoma.
  • To evaluate gemcitabine's role in advanced hematological malignancies.

Main Methods:

  • Weekly gemcitabine administration (1 g/m2) in cycles of 7 weeks on, 1 week off, followed by 3 weeks on, 1 week off.
  • Treatment continued until disease progression or intolerance.
  • Fifteen heavily pre-treated patients with advanced diffuse large-cell or mantle-cell lymphoma enrolled.

Related Experiment Videos

Main Results:

  • Gemcitabine was well tolerated; no treatment-related sepsis, hemorrhage, or death occurred.
  • Two patients discontinued therapy due to non-hematopoietic toxicity.
  • Among 13 evaluable patients: 1 complete response, 3 partial responses, 3 stable disease, 6 disease progression.
  • One patient with Hodgkin's disease achieved a 21-month complete remission after 6 infusions.

Conclusions:

  • Gemcitabine exhibits significant activity and acceptable toxicity in heavily pre-treated advanced lymphoma patients.
  • Further investigation of gemcitabine in lymphoma treatment is warranted.